Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genfit S.A. ADR
(NQ:
GNFT
)
3.650
UNCHANGED
Streaming Delayed Price
Updated: 2:50 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
3.650
Bid (Size)
3.480 (46)
Ask (Size)
3.520 (10)
Prev. Close
3.650
Today's Range
3.650 - 3.650
52wk Range
2.893 - 4.750
Shares Outstanding
38,888,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
December 28, 2023
The company is working on the first treatment that could make a difference in the itching associated with a liver disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 14, 2023
Via
Benzinga
Performance
YTD
-9.43%
-9.43%
1 Month
N/A
N/A
3 Month
-6.41%
-6.41%
6 Month
+10.94%
+10.94%
1 Year
-10.54%
-10.54%
More News
Read More
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
September 08, 2023
Via
Investor's Business Daily
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
July 13, 2023
Via
Benzinga
Analyst Expectations for Genfit's Future
July 03, 2023
Via
Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
June 30, 2023
Via
Benzinga
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022
Via
Benzinga
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
June 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 30, 2023
Via
Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
June 30, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 30, 2023
Via
InvestorPlace
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
June 23, 2023
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 22, 2023
Via
Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
Via
Benzinga
Earnings Scheduled For April 13, 2023
April 13, 2023
Via
Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
February 07, 2023
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 10, 2022
Via
Benzinga
Earnings Scheduled For September 28, 2022
September 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 22, 2022
Via
Benzinga
US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
September 14, 2022
Via
Benzinga
BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday
September 14, 2022
Via
Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
September 13, 2022
Via
Benzinga
GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
September 13, 2022
Via
Benzinga
Analyzing Genfit's Short Interest
August 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
July 11, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.